Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$40.00 -0.2%	$35.80	$21.62 ▼ $41.71	$7.61B	1.1	2.51 million shs	3.26 million shs
BPMC Blueprint Medicines	$128.12 -0.1%	$102.85	$73.04 ▼ $128.34	$8.28B	0.84	1.24 million shs	3.48 million shs
CORT Corcept Therapeutics	$71.24 -0.8%	$71.43	$28.10 ▼ $117.33	$7.62B	0.19	1.14 million shs	907,284 shs
SESN Sesen Bio		$10.50	$0.37 ▼ $12.58	$2.56B	0.83	1.07 million shs	93,330 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.17%	+2.43%	+18.73%	+17.96%	+44.88%
BPMC Blueprint Medicines	-0.09%	+0.13%	+26.59%	+44.82%	+20.06%
CORT Corcept Therapeutics	-0.85%	0.00%	-4.78%	+23.70%	+153.07%
SESN Sesen Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.6858 of 5 stars	4.5	2.0	0.0	3.9	3.3	3.3	0.6
BPMC Blueprint Medicines	1.0764 of 5 stars	2.1	2.0	0.0	0.0	1.9	0.8	0.6
CORT Corcept Therapeutics	4.6606 of 5 stars	3.5	1.0	0.0	4.2	3.2	4.2	1.9
SESN Sesen Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$56.67	41.67% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.05% Downside
CORT Corcept Therapeutics	3.00	Buy	$138.25	94.06% Upside
SESN Sesen Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SESN, BPMC, CORT, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	34.23	N/A	N/A	($7.71) per share	-5.19
BPMC Blueprint Medicines	$508.82M	16.26	N/A	N/A	$4.70 per share	27.26
CORT Corcept Therapeutics	$675.04M	11.19	$1.23 per share	57.85	$6.49 per share	10.98
SESN Sesen Bio	$40M	0.00	N/A	3.39	$0.78 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.11	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
CORT Corcept Therapeutics	$141.21M	$1.16	61.41	38.51	N/A	19.33%	20.40%	16.64%	8/4/2025 (Estimated)
SESN Sesen Bio	-$19.88M	-$0.10	N/A	N/A	N/A	N/A	6.70%	5.41%	N/A

Latest SESN, BPMC, CORT, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
SESN Sesen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
BPMC Blueprint Medicines	1.01	2.80	2.75
CORT Corcept Therapeutics	N/A	3.07	2.96
SESN Sesen Bio	N/A	6.10	6.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
CORT Corcept Therapeutics	93.61%
SESN Sesen Bio	16.45%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BPMC Blueprint Medicines	4.21%
CORT Corcept Therapeutics	20.80%
SESN Sesen Bio	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
CORT Corcept Therapeutics	300	106.04 million	83.99 million	Optionable
SESN Sesen Bio	35	203.49 million	196.98 million	Optionable

SESN, BPMC, CORT, and BBIO Headlines

Recent News About These Companies

Trey Mewes

April 10, 2024 | startribune.com

Devin Haney: biography, record, fights and more

December 9, 2023 | espn.com

Tyson Fury: Biography, record, fights and more

December 2, 2023 | espn.com

Why the Tucker Carlson Biography Sales Are So Pathetic

September 13, 2023 | thedailybeast.com

Sesen Bio (NASDAQ: SESN)

August 4, 2023 | fool.com

James McTeigue Biography & Movies

May 10, 2023 | tribute.ca

After revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen Bio

March 6, 2023 | bizjournals.com

Sesen Bio wins shareholder approval for Carisma merger

March 2, 2023 | msn.com

Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

March 2, 2023 | finance.yahoo.com

Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results

February 28, 2023 | finance.yahoo.com

SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigations

February 24, 2023 | benzinga.com

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carisma

February 21, 2023 | finance.yahoo.com

BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics

February 17, 2023 | stockhouse.com

Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting

February 16, 2023 | businesswire.com

Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger

February 16, 2023 | finance.yahoo.com

Sesen Bio reaches deal with investor group, paving way for Carisma merger

February 15, 2023 | endpts.com

Latest terms of Sesen Bio and Carisma merger appear to pass muster

February 15, 2023 | thepharmaletter.com

5 big dividend moves: Group 1 Automotive hikes by 20% | Pro Recap

February 15, 2023 | finance.yahoo.com

BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics

February 15, 2023 | finance.yahoo.com

Sesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor group

February 14, 2023 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SESN, BPMC, CORT, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$40.00 -0.07 (-0.17%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$40.01 +0.01 (+0.02%)

As of 06/18/2025 08:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

$128.12 -0.11 (-0.09%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$128.14 +0.02 (+0.02%)

As of 06/18/2025 07:11 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Corcept Therapeutics NASDAQ:CORT

$71.24 -0.61 (-0.85%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$71.28 +0.05 (+0.06%)

As of 06/18/2025 06:03 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Sesen Bio NASDAQ:SESN

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time